MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for…
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S.…
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused…
2024 Albert B. Sabin Gold Medal and 2024 Sabin Rising Star Award Presentations Dr. Keith Klugman (left) and Dr. Shabir…
LOWELL, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences…
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live…
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for…
EO2401, a pioneering OncoMimics™ peptide-based immunotherapy, has demonstrated rapid activation and significant expansion of existing effector memory T cells against…
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a…